


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3504016/publications.pdf Version: 2024-02-01



\\/FI\\/FI

#	Article	IF	CITATIONS
1	Risk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples. Journal of the National Cancer Institute, 2014, 106, .	6.3	184
2	FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. Journal of Clinical Investigation, 2013, 123, 4435-4448.	8.2	76
3	Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. Journal of the National Cancer Institute, 2017, 109, .	6.3	74
4	Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clinical Cancer Research, 2015, 21, 4960-4969.	7.0	62
5	Targeting the Nuclear Import Receptor Kpn $\hat{1}^21$ as an Anticancer Therapeutic. Molecular Cancer Therapeutics, 2016, 15, 560-573.	4.1	57
6	NDRG1 overexpression promotes the progression of esophageal squamous cell carcinoma through modulating Wnt signaling pathway. Cancer Biology and Therapy, 2016, 17, 943-954.	3.4	42
7	A genomeâ€scale metabolic network model and machine learning predict amino acid concentrations in Chinese Hamster Ovary cell cultures. Biotechnology and Bioengineering, 2021, 118, 2118-2123.	3.3	37
8	The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 509-519.	2.5	34
9	Ovarian cancer: genomic analysis. Annals of Oncology, 2013, 24, x7-x15.	1.2	29
10	Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2015, 17, 374-381.	2.8	22
11	Systematic evaluation of parameters for genome-scale metabolic models of cultured mammalian cells. Metabolic Engineering, 2021, 66, 21-30.	7.0	16
12	Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer. Cancer Cell, 2015, 28, 7-9.	16.8	15
13	Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target. Oncotarget, 2017, 8, 96482-96495.	1.8	15
14	Oncogenic but non-essential role of N-myc downstream regulated gene 1 in the progression of esophageal squamous cell carcinoma. Cancer Biology and Therapy, 2013, 14, 164-174.	3.4	14
15	Inhibition of Kpnβ1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer. BMC Cancer, 2021, 21, 106.	2.6	12
16	Abstract PR05: An assessment of the prognostic and predictive associations of 13 angiogenic biomarkers in women with newly diagnosed advanced ovarian cancer treated with chemotherapy with or without bevacizumab. , 2015, , .		1
17	Abstract 2355: Risk prediction for late-stage ovarian cancer by meta-analysis of 1,525 patient samples. , 2014, , .		1
18	Abstract 5401: TGF-β signaling inhibition as a potential approach to target suboptimally debulked ovarian tumors. , 2015, , .		1

2

WEI WEI

#	Article	IF	CITATIONS
19	The genomic of epithelial ovarian cancer: the past, present, and future. Annals of Oncology, 2015, 26, vii27.	1.2	0
20	Abstract 1072: The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer. , 2012, , .		0
21	Abstract 3013: Elucidating the functional role of microfibril-associated glycoprotein-2 (MACP-2) in human ovarian cancer , 2013, , .		0
22	Abstract 3001: Aberrantly up-regulated synaptotagmin-like 2 (SYTL2) promotes tumorigenesis of ovarian cancer cells , 2013, , .		0